EUCTR2016-003278-42-ES进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Episodic Cluster Headache
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •a.Patients are capable of giving signed informed consent as described in Appendix D which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •b.The patient is a man or woman 18 to 70 years of age, inclusive.
- •c.The patient has a history of ECH according to ICHD-3 beta criteria (Headache Classification Committee of the IHS 2013) for =12 months prior to screening including the following:
- •-Attacks of severe, strictly unilateral pain which is orbital, supraorbital, temporal or in any combination of these sites, lasting 15 to 180 minutes and occurring from once daily every other day to 8 times a day for more than half of the time when the disorder is active
- •-The pain is associated with at least 1 of the following symptoms or signs: ipsilateral conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, forehead and facial sweating, miosis and/or ptosis and/or eyelid oedema, and/or sense of restlessness or agitation.
- •-CH attacks occurring in periods lasting from 7 days to 1 year, separated by pain-free periods lasting at least 1 month.
- •-CH attacks have started no more than 2 weeks (15 days, inclusive) prior to screening and, based on the patient’s previous medical history, it is expected that the patient’s CH attacks will continue for =6 weeks after the screening visit.
- •d.The patient has a total body weight of =45 kg
- •e.The patient is not using or using a maximum of 2 concomitant medications that are commonly prescribed as preventive treatments for CH , regardless of the indication for which the medication was prescribed. Patients must be on a stable dose and regimen for at least 2 weeks prior to screening and throughout the study.
- •f.The patient has demonstrated compliance with the electronic headache diary during the run-in period by entry of headache data on 85% of days during the run-in period.
- •g.The patient has at least 7 CH attacks during the run-in period.
- •h.The patient is in good health in the opinion of the investigator as determined by a medical and psychiatric history; medical examination; 12 lead ECG; and serum chemistry, hematology, coagulation, and urinalysis.
- •i.Women may be included only if they have a negative serum beta-human chorionic gonadotropin (ß-HCG) test at screening, are sterile, or postmenopausal.
- •j.Women of childbearing potential (WOCBP) whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the study (ie, starting at screening) and for 7.5 months after discontinuation of IMP.
- •k.Men must be sterile, or if they are potentially fertile/reproductively competent (not surgically [eg, vasectomy] or congenitally sterile) and their female partners are of childbearing potential, must use, together with their female partners, acceptable birth control methods for the duration of the study and for 7.5 months after discontinuation of the IMP. Definitions of WOCBP, sterile, and postmenopausal women; male contraception; and highly effective and acceptable birth control methods
- •l.The patient must be willing and able to comply with study restrictions, to remain at the clinic for the required duration during the study period and to
排除标准
- •a.The patient has used short corticosteroid cycle to treat the current CH cycle.
- •b.The patient reports using butalbital on more than 7 days during the 4 weeks prior to screening or using butalbital on more than 3 days during the screening/run-in period.
- •c.The patient reports using opioids on more than 15 days during the 4 weeks prior to screening or using opioids on more than 4 days during the screening/run-in period.
- •d.The patient has used an intervention/device (eg, scheduled nerve blocks) for headache during the 4 weeks prior to screening.
- •e.The patient has clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, genitourinary, cardiac, neurologic, hepatic, or ocular disease at the discretion of the investigator.
- •f.The patient has evidence or medical history of clinically significant psychiatric issues determined at the discretion of the investigator.
- •g.The patient has a history of any suicide attempt in the past or current active suicidal ideation, as measured by the eC-SSRS.
- •h.The patient has a history of clinically significant cardiovascular disease or vascular ischemia (such as myocardial, neurological [eg, cerebral ischemia], peripheral extremity ischemia, or other ischemic event) or thromboembolic events (arterial or venous thrombotic or embolic events), such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism
- •i.The patient has known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection.
- •j.The patient has a past or current history of cancer in the past 5 years, except for appropriately treated non-melanoma skin carcinoma.
- •k.The patient is pregnant or nursing.
- •l.The patient has a history of hypersensitivity reactions to injected proteins, including monoclonal antibodies.
- •m.The patient has participated in a clinical study of a new chemical entity or a prescription medicine within 2 months or 5 half-lives before administration of the first dose of the IMP, whichever is longer.
- •n.The patient has participated in a clinical study of a monoclonal antibody, unless it is known that the patient received placebo during the study.
- •o.The patient has a history of prior exposure to a monoclonal antibody targeting the CGRP pathway (AMG 334, ALD304, LY2951742, or fremanezumab).
- •p.The patient has any finding in the baseline 12 lead ECG considered clinically significant in the judgment of the investigator.
- •q.The patient has any finding that, in the judgment of the investigator, is a clinically significant abnormality, including serum chemistry, hematology, coagulation, and urinalysis test values (abnormal tests may be repeated for confirmation).
- •r.The patient has hepatic enzymes (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) >1.5 × the upper limit of normal (ULN) range after confirmation in a repeat test, or the patient has suspected hepatocellular damage that fulfills criteria for Hy’s law at screening.
- •s.The patient has serum creatinine >1.5 × the ULN or evidence of clinically significant renal disease in the judgement of the investigator.
- •t.The patient cannot participa
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel group, Dose Response Study of subcutaneous AVE5026 with an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery - TREKPatients undergoing elective total knee replacement surgery (risk of venous thromboembolic event)MedDRA version: 8.1Level: LLTClassification code 10049909EUCTR2005-006202-26-NOSanofi-Aventis Recherche et Développement800
已完成
3 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,<br>Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens<br>(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the<br>Prevention of Chronic Cluster HeadacheCluster HeadacheNL-OMON45623TEVA Pharma20
进行中（未招募）
1 期
Clinical trial investigating the efficacy and safety of investigational drug TEV-48125 developed to prevent chronic cluster headacheEUCTR2016-003171-21-DETeva Branded Pharmaceutical Products R&D, Inc.300
撤回
3 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,<br>Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens<br>(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the<br>Prevention of Episodic Cluster HeadacheCluster HeadacheNL-OMON47278TEVA Pharma20
进行中（未招募）
1 期
This is a Phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18 – 75 years of age) with moderate to severe AD who are candidates for systemic therapy. The study is comprised of a 35-day Screening Period, a 24-week blinded treatment period, and a 12-week Follow-up period.moderate to severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-002264-57-HRAbbVie Deutschland GmbH & Co. KG650